Jacques Rouanet Selected Research

Melanoma (Melanoma, Malignant)

7/2023	Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
10/2022	Metastatic melanoma treated by immunotherapy: discovering prognostic markers from radiomics analysis of pretreatment CT with feature selection and classification.
4/2022	Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol.
3/2021	Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma.
1/2021	Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments.
1/2021	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy.
10/2020	Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
5/2020	'Aberrant localisation of Annexin A1 is associated with metastatic outcome in thin melanomas'.
11/2019	Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms.
4/2019	Determination of eumelanin and pheomelanin in melanomas using solid-phase extraction and high performance liquid chromatography-diode array detection (HPLC-DAD) analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jacques Rouanet Research Topics

Disease

10	Melanoma (Melanoma, Malignant) 07/2023 - 04/2019
6	Neoplasms (Cancer) 04/2022 - 04/2019
1	Skin Neoplasms (Skin Cancer) 07/2023
1	Arthritis (Polyarthritis) 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2022
1	Chondrosarcoma 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Osteoarthritis 01/2022
1	Bullous Pemphigoid (Pemphigoid) 01/2022
1	Disease Progression 01/2022
1	Arthralgia (Joint Pain) 01/2022
1	Hematologic Diseases (Blood Diseases) 11/2021
1	Lymphatic Metastasis 03/2021
1	Extranodal Extension 03/2021
1	Circulating Neoplastic Cells 11/2019
1	Pityriasis Rubra Pilaris 01/2018

Drug/Important Bio-Agent (IBA)

5	Radioisotopes (Radionuclides)IBA 04/2022 - 11/2019
4	N- (2- diethylaminoethyl)- 6- iodoquinoxaline- 2- carboxamideIBA 04/2022 - 11/2019
4	Melanins (Melanin)IBA 04/2022 - 11/2019
3	Immune Checkpoint InhibitorsIBA 07/2023 - 10/2020
2	benzamideIBA 04/2022 - 01/2021
1	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2022
1	HhAntag691IBA 01/2022
1	Bexarotene (LGD1069)FDA Link 01/2022
1	Aromatase InhibitorsIBA 01/2022
1	AntibodiesIBA 11/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 03/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	LigandsIBA 10/2020
1	Annexin A1IBA 05/2020
1	AnionsIBA 04/2019
1	pheomelaninIBA 04/2019
1	eumelaninIBA 04/2019
1	apremilastIBA 01/2018

Therapy/Procedure

7	Therapeutics 04/2022 - 11/2019
2	Immunotherapy 10/2022 - 10/2020
1	Radiotherapy 01/2022
1	Stem Cell Transplantation 11/2021